Prolia (Denosumab) Cost in Minnesota: 2026 Pricing, Insurance, and Savings Guide

What Prolia (Denosumab) Costs in Minnesota Without Insurance

The average cash-pay price for a single Prolia injection at Minnesota retail pharmacies sits near $1,500 in 2026, matching Amgen's wholesale acquisition cost. Because Prolia is dosed every six months, the annual out-of-pocket burden for uninsured patients reaches approximately $3,000.

Why Cash Prices Vary Across Minnesota

Retail pharmacy pricing in Minnesota is not fixed. Specialty pharmacies in the Twin Cities metro area, Duluth, and Rochester may quote prices ranging from $1,350 to $1,650 per dose depending on their acquisition agreements with Amgen. Hospital outpatient infusion centers often bill differently than retail specialty pharmacies. The drug is classified as a physician-administered injectable under Medicare Part B (J-code J0897), which means many patients receive it in a clinic rather than picking it up at a pharmacy counter.

Cash-Pay Reduction Strategies

Patients paying out of pocket should ask their prescribing clinic whether they participate in buy-and-bill arrangements, which can sometimes yield lower per-dose costs than retail channels. Discount aggregator platforms may also list coupons, though denosumab discounts through these platforms rarely dip below $1,200 per dose in Minnesota.

Minnesota Medicaid Coverage for Prolia

Minnesota Medical Assistance (Medicaid) covers Prolia with prior authorization. The state's preferred drug list, managed by the Minnesota Department of Human Services, includes denosumab for postmenopausal women with osteoporosis who meet specific clinical criteria.

Prior Authorization Requirements

To obtain PA approval, prescribers typically must document a T-score of -2.5 or lower on DXA scan, or a history of fragility fracture, consistent with the FREEDOM trial enrollment criteria. The PA process also generally requires evidence that the patient has tried or cannot tolerate an oral bisphosphonate such as alendronate. Approval periods usually run 12 months and require renewal with updated clinical documentation.

MinnesotaCare and Managed Medicaid Plans

MinnesotaCare enrollees follow a similar formulary structure. Managed care organizations contracted with Minnesota Medicaid, including UCare, Hennepin Health, and Blue Plus, each maintain their own PA forms but apply comparable coverage criteria. Processing times range from 24 to 72 hours for standard requests and under 24 hours for urgent cases.

Commercial Insurance Coverage in Minnesota

Most major commercial insurers operating in Minnesota cover Prolia, though placement on formulary tiers and cost-sharing structures differ.

Blue Cross Blue Shield of Minnesota

BCBS of MN generally covers Prolia on its specialty tier. Patients should expect a coinsurance rate of 20% to 30% after meeting their deductible, unless the Amgen Savings Card or a copay assistance program offsets that amount. Step therapy requiring a trial of generic alendronate is standard.

UnitedHealthcare and Medica

UnitedHealthcare plans sold in the Minnesota marketplace typically place Prolia on specialty tier with prior authorization. Medica, one of the state's largest regional carriers, follows a similar model. Both insurers accept PA documentation showing bisphosphonate failure, intolerance, or contraindication (such as esophageal disorders or renal impairment with eGFR <35 mL/min).

Medicare Part B in Minnesota

Prolia falls under Medicare Part B as a physician-administered drug rather than Part D. Medicare pays 80% of the allowable amount after the Part B deductible ($257 in 2025). The remaining 20% coinsurance, roughly $300 per injection, can be covered by a Medigap supplemental plan. Medicare Advantage plans in Minnesota must cover Prolia at least as well as Original Medicare.

The Amgen Savings Card: How It Works in Minnesota

Amgen offers the Prolia Savings Card specifically for commercially insured patients. The card covers up to $1,500 in out-of-pocket costs per injection, effectively reducing copays or coinsurance to $0 for many patients.

Eligibility Rules

The card is available to patients with commercial (private) insurance. It excludes those enrolled in Medicare, Medicaid, Tricare, or any other federal or state government healthcare program. Minnesota residents with employer-sponsored plans, ACA marketplace plans, or individual commercial policies qualify. Patients can enroll at Amgen's patient support site or through their prescriber's office.

How the Card Applies at the Point of Sale

When a patient receives Prolia at a physician's office, the billing staff submits the claim to the primary insurer first. After the insurer adjudicates the claim and determines the patient's cost-sharing responsibility, the Amgen Savings Card is applied as secondary coverage. If the patient's coinsurance is $400, the card pays that $400. The patient pays nothing out of pocket unless their coinsurance exceeds the $1,500 per-dose cap, which is uncommon for most commercial plans.

Annual Limits and Renewal

The program covers up to two injections per year (matching the every-six-month dosing schedule). Patients must re-enroll annually. Amgen reserves the right to modify or discontinue the program, so patients should confirm current terms at each visit.

Compounded Denosumab in Minnesota

Compounded denosumab is available in Minnesota through licensed 503A pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Legal Status

Minnesota permits 503A compounding pharmacies to prepare denosumab formulations when a prescriber writes a patient-specific prescription. The Minnesota Board of Pharmacy oversees compounding pharmacy licensure and inspections. Patients should verify that any compounding pharmacy holds a current Minnesota license and follows USP <797> sterile compounding standards.

Cost Differences

Compounded versions may carry lower per-dose costs than brand Prolia, though pricing varies by pharmacy. Some 503A pharmacies advertise compounded denosumab at significantly reduced prices. Patients considering this route should discuss bioequivalence expectations with their prescriber, as compounded biologics are not FDA-approved and do not undergo the same manufacturing validation as Amgen's commercial product.

Clinical Considerations

The FREEDOM trial (N=7,868) demonstrated that branded denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [1]. These results apply specifically to the manufactured product. No large randomized trials have evaluated compounded denosumab formulations, so patients opting for compounded versions are making a decision with less supporting evidence.

Telehealth Prescribing of Prolia in Minnesota

Minnesota permits telehealth prescribing of Prolia. A licensed prescriber can evaluate a patient via synchronous audio-video visit and write a prescription for denosumab without an in-person encounter, provided they establish an appropriate provider-patient relationship.

Practical Limitations

While the prescription itself can originate from a telehealth visit, the injection must be administered subcutaneously by a healthcare professional. Most patients receive Prolia in a clinic, physician office, or infusion center. Telehealth is most useful for the initial evaluation, treatment planning, follow-up bone density review, and ongoing monitoring rather than the actual drug administration.

Minnesota Telehealth Parity Laws

Minnesota's telehealth parity statute requires that commercial insurers cover telehealth visits for prescribing decisions at the same rate as in-person visits. This means the consultation leading to a Prolia prescription should not carry additional out-of-pocket costs beyond what the patient would pay for an office visit. Medicaid also covers telehealth encounters under the same parity framework.

Discount Programs and Patient Assistance Beyond the Savings Card

Several additional cost-reduction pathways exist for Minnesota residents who cannot afford Prolia.

Amgen Safety Net Foundation

Amgen operates the Safety Net Foundation, a patient assistance program for uninsured or underinsured patients. Qualifying individuals may receive Prolia at no cost. Income eligibility is typically set at 400% of the federal poverty level or below, though Amgen updates thresholds periodically. Applications require documentation of income, insurance status, and a valid prescription.

Hospital Financial Assistance Programs

Minnesota hospitals, including those in the Mayo Clinic Health System, Allina Health, and Essentia Health networks, maintain financial assistance policies as required by Minnesota and federal law. Patients receiving Prolia at a hospital outpatient clinic may qualify for reduced-cost or free care under these programs if their income falls below certain thresholds.

340B Drug Pricing

Some clinics in Minnesota, particularly federally qualified health centers (FQHCs) and certain safety-net hospitals, participate in the 340B Drug Pricing Program, which allows them to purchase Prolia at a substantially discounted rate. Patients treated at 340B-covered entities may benefit from lower out-of-pocket costs, depending on the entity's billing practices.

Clinical Context: Why Prolia Is Prescribed

Denosumab is a fully human monoclonal antibody that inhibits RANK ligand (RANKL), a protein required for the formation, function, and survival of osteoclasts. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density.

FDA-Approved Indications

The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high risk for fracture [2]. Subsequent approvals expanded the indication to men with osteoporosis, patients receiving aromatase inhibitor therapy for breast cancer, patients on androgen deprivation therapy for prostate cancer, and glucocorticoid-induced osteoporosis.

Efficacy Data

In the FREEDOM trial published in the New England Journal of Medicine, denosumab 60 mg subcutaneously every six months reduced the incidence of new radiographic vertebral fractures to 2.3% versus 7.2% with placebo over 36 months (relative risk reduction 68%, P<0.001) [1]. The FREEDOM Extension study followed patients for up to 10 years and reported continued fracture risk reduction with sustained treatment, with lumbar spine BMD increasing by 21.7% from baseline [3].

Dr. Steven Cummings, one of the FREEDOM investigators, noted: "The sustained gains in bone density over a decade of continuous treatment distinguish denosumab from bisphosphonates, where BMD gains typically plateau after 3 to 5 years."

Discontinuation Risk

Clinicians and patients should be aware that stopping Prolia leads to rapid bone loss. The Endocrine Society and American Association of Clinical Endocrinology recommend transitioning to a bisphosphonate (typically zoledronic acid) after discontinuing denosumab to prevent rebound vertebral fractures [4]. A 2017 analysis identified multiple vertebral fractures occurring within 7 to 16 months of denosumab cessation in patients who did not receive follow-on therapy [5].

As stated in the 2020 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis: "Patients discontinuing denosumab should receive an antiresorptive agent, preferably a bisphosphonate, to mitigate the risk of rebound bone turnover and vertebral fractures."

Comparing Minnesota Prolia Costs to National Averages

Minnesota's average cash-pay price of $1,500 per dose aligns closely with the national median. States with higher concentrations of specialty pharmacies, such as California and New York, may see slightly more price variation, but the wholesale acquisition cost set by Amgen remains the pricing floor nationwide. Minnesota patients do not face a state-specific markup or tax disadvantage for specialty medications, as Minnesota exempts prescription drugs from state sales tax.